Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ascendis Pharma A/S (ASND) vs Kinross Gold Corporation (KGC) Price & Performance

Ascendis Pharma A/STrade
Kinross Gold CorporationTrade

Price performance (Past 24H)

Key statistics

Ascendis Pharma A/S vs Kinross Gold Corporation — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.67B), while Kinross Gold Corporation trades at $27.51 (market cap $32.29B). The key difference: Kinross Gold Corporation is the larger of the two by market cap, and Kinross Gold Corporation pays a 0.59% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.

ASNDKGC
Market Cap
$16.67B$32.29B
Sector
HealthBasic Materials
52-Week High
$277.18$38.06
52-Week Low
$189.74$18.70
Enterprise Value
$17.04B$30.37B
Dividend Yield
0.59%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ascendis Pharma A/S

Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.

ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.

Kinross Gold Corporation

Kinross Gold (KGC) trades at $27.70, up 1.09% today, with a bullish technical signal from moving averages but overbought RSI levels. The company demonstrates robust fundamentals, with Q2 2026 EPS beating estimates at $0.71 versus $0.66 expected, and strong cash flow growth, with 2025 operating cash flow at $3.76 billion. Recent news includes a credit rating upgrade to 'BBB' by S&P Global Ratings on August 6, 2026, and ongoing project developments like Lobo-Marte.

The outlook is positive, supported by earnings beats, rising gold prices, and a consensus price target of $37.20, implying 34% upside. Risks include cost pressures and gold price volatility, but institutional buying and a 58.6% analyst buy rating suggest confidence in continued growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.

Read more on ASND

About Kinross Gold Corporation

Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.

Read more on KGC